NCI Funds 4-Year Projects at 12 Tobacco Research Centers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 12
Volume 9
Issue 12

BETHESDA, Md-The National Cancer Institute (NCI) has launched its new antismoking initiative, Research in State and Community Tobacco Control Interventions, by awarding 12 grants totaling $13 million. The money will support the first year of 4-year research projects on local, state, and multistate tobacco prevention and control programs.

BETHESDA, Md—The National Cancer Institute (NCI) has launched its new antismoking initiative, Research in State and Community Tobacco Control Interventions, by awarding 12 grants totaling $13 million. The money will support the first year of 4-year research projects on local, state, and multistate tobacco prevention and control programs.

The first awards in the NCI program went to researchers at the University of Alabama at Birmingham; AMC Cancer Research Center, Denver; University of Illinois at Chicago; Battelle Centers for Public Health Research and Evaluation, Baltimore; and University of Massachusetts campuses at Amherst and Boston.

Grants also went to the University of Massachusetts Medical School; University of Minnesota School of Public Health; Roswell Park Cancer Institute; Oregon Research Institute, Eugene; Kaiser Permanente Center for Health Research, Portland, Oregon; and University of Texas Health Science Center at Houston.

Recent Videos
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content